Immunotherapy boosts rectal cancer treatment in early trial
NCT ID NCT03921684
First seen Jan 10, 2026 · Last updated May 10, 2026 · Updated 19 times
Summary
This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy and radiation can improve outcomes for people with locally advanced rectal cancer. About 29 participants who have not had prior treatment will receive the combination before surgery. The main goal is to see if the cancer completely disappears after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel
Conditions
Explore the condition pages connected to this study.